Description

Levetiracetam Grindex Coated Tablets 500 mg. №30

Ingredients:

Each coated tablet contains 500 mg of Levetiracetam.

Dosage:

The usual dose is 1000 mg (2 tablets) twice daily. Dosage may vary based on individual patient needs.

Indications:

Levetiracetam Grindex is indicated for the treatment of epilepsy. It is used alone or with other medications to control seizures.

Contraindications:

Do not use Levetiracetam Grindex if you are allergic to levetiracetam or any other ingredients in the product. Consult your doctor before starting this medication.

Directions:

Swallow the tablets whole with a full glass of water. It can be taken with or without food. Follow your doctor’s instructions carefully.

Scientific Evidence:

Levetiracetam has been extensively studied for its efficacy in controlling seizures. Research published in the journal Epilepsy Research demonstrated that Levetiracetam is effective in reducing seizure frequency and improving quality of life in patients with epilepsy.

Additional Information:

It is important to take Levetiracetam Grindex regularly to get the most benefit. Do not stop taking the medication without consulting your doctor. Inform your healthcare provider about all the medications you are currently taking to avoid any interactions.

Pharmacological Effects:

Levetiracetam works by stabilizing electrical activity in the brain, which helps prevent abnormal bursts of electrical activity that can lead to seizures. It is believed to act by binding to a specific protein in the brain called synaptic vesicle protein 2A (SV2A).

Clinical Trials and Comparative Effectiveness:

Clinical trials have shown that Levetiracetam is as effective as other antiepileptic drugs in controlling seizures with a favorable side effect profile. A study published in Neurology compared the efficacy of Levetiracetam with carbamazepine and found similar seizure control rates between the two medications.

Overall, Levetiracetam Grindex coated tablets 500 mg. №30 are a well-tolerated and effective treatment option for individuals with epilepsy, supported by scientific evidence and clinical trials.